Sign In
Buy DSS
$0.600
+0.0649 (+12.13%)
At Close: Jun 22, 2026
DSS, Inc. Withdraws Registration Statement
10:15am, Tuesday, 09'th Jun 2026
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Ex
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
05:00pm, Friday, 08'th May 2026
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes
DSS, Inc. Letter to Shareholders
04:31pm, Wednesday, 15'th Apr 2026
ROCHESTER, N. Y. , April 15, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today issued the following letter to shareholders from the Interim CEO, Jason Grady, highlighting the Company's ope
DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering
09:45am, Thursday, 05'th Feb 2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology,
DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering
08:35am, Wednesday, 04'th Feb 2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercia
DSS, Inc. Announces Launch of Proposed Public Offering
08:17pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
08:31am, Thursday, 22'nd May 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, toda
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
08:30am, Wednesday, 26'th Feb 2025
ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air pu
DSS, Inc. Issues Letter to Shareholders
08:50am, Monday, 03'rd Feb 2025
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops asset
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
04:26pm, Monday, 16'th Sep 2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful
AmericaFirst Funds Trust Announces Changes to Board of Trustees
09:00am, Tuesday, 10'th Sep 2024
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and Alla
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer
04:08pm, Monday, 26'th Aug 2024
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as C
Yugabyte Embraces ‘No Downtime, No Limits,’ as the Theme of the Upcoming Distributed SQL Summit Asia
09:07pm, Wednesday, 17'th Apr 2024
Experts and Executives from Airwallex, Helpshift, IMDA, Navi, Rakuten, Singtel, Tagbangers, and UL Systems to Present at the Virtual Event SUNNYVALE, Calif.–(BUSINESS WIRE)–Yugabyte, the leading o
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
08:05am, Tuesday, 30'th Jan 2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Lae
